Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kiora PharmaceuticalsFRA:7EY 34 5-Year Share Buyback Ratio is -236.10 as of Jun. 2026. GuruFocus rates FRA:7EY with a GF Score™ of 34/100. The stock has 4 warning signs investors should review. Among 1,121 Biotechnology companies, Kiora Pharmaceuticals ranks worse than 98.66% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Kiora Pharmaceuticals's current 5-Year Share Buyback Ratio was -236.10%.
FRA:7EY's 5-Year Share Buyback Ratio is ranked worse than 98.66% of 1121
companies
in the Biotechnology industry
Industry Median: -10.2
vs FRA:7EY: -236.10
Kiora Pharmaceuticals (FRA:7EY) 5-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Kiora Pharmaceuticals 5-Year Share Buyback Ratio Related Terms
FRA:7EY vs SNTI, PDSB, TOVX: 5-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Kiora Pharmaceuticals's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiora Pharmaceuticals 5-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's 5-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Kiora Pharmaceuticals's 5-Year Share Buyback Ratio falls into.
Kiora Pharmaceuticals 5-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 5-Year Share Buyback Ratio of -236.10 mean?
Kiora Pharmaceuticals (FRA:7EY) has a 5-Year Share Buyback Ratio of -236.10 as of Jun. 2026. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Kiora Pharmaceuticals and its competitors. According to the industry distribution chart, Kiora Pharmaceuticals ranks #1106 out of 1121 companies in the Biotechnology industry, placing it in the top 98.7%.
Is Kiora Pharmaceuticals' 5-Year Share Buyback Ratio too high?
Kiora Pharmaceuticals' current 5-Year Share Buyback Ratio is -236.10. Based on the distribution chart, Kiora Pharmaceuticals ranks #1106 out of 1121 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kiora Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Kiora Pharmaceuticals' 5-Year Share Buyback Ratio compare to SNTI and PDSB?
According to the Biotechnology industry distribution chart, Kiora Pharmaceuticals ranks #1106 out of 1121 companies for 5-Year Share Buyback Ratio. This places Kiora Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Share Buyback Ratio for a Biotechnology company?
A good 5-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 5-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Share Buyback Ratio mean?
A high 5-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Kiora Pharmaceuticals and its competitors. Kiora Pharmaceuticals's current 5-Year Share Buyback Ratio is -236.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiora Pharmaceuticals stock overvalued right now?
Kiora Pharmaceuticals (FRA:7EY) has a current 5-Year Share Buyback Ratio of -236.10. The current 5-Year Share Buyback Ratio is -236.10. Kiora Pharmaceuticals' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Share Buyback Ratio calculated?
5-Year Share Buyback Ratio is calculated from a company's financial statements. For Kiora Pharmaceuticals (FRA:7EY), the current 5-Year Share Buyback Ratio is -236.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology company based in the United States that develops therapies for orphan retinal diseases and inflammatory eye conditions. Its lead candidate, KIO-301, is a molecular photoswitch designed to restore vision in patients with inherited or age-related retinal degeneration, including retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a next-generation, non-steroidal, immunomodulatory small-molecule inhibitor of dihydroorotate dehydrogenase, for posterior non-infectious uveitis. Kiora targets specialty ophthalmic markets, focusing on conditions with limited treatment options and orphan drug designations. As a clinical-stage company, it does not yet generate product revenue; its operations are funded primarily through equity financings, partnerships, and research collaborations, with value expected to be driven by clinical trial progress and regulatory milestones.
34GF Score
Get the complete analysis for FRA:7EY
5-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7EY has been successfully added to your 
